Showing 2471-2480 of 4063 results for "".
- Regenxbio Announces Lancet Publication of Phase 1/2a Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMDhttps://modernod.com/news/regenxbio-announces-lancet-publication-of-phase-12a-study-evaluating-abbv-rgx-314-as-a-one-time-gene-therapy-for-wet-amd/2482186/Regenxbio announced the publication of results from the phase 1/2a trial evaluating the safety and tolerability of a single dose of subretinal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD). Two-year data were
- NewSight Reality Unveils Transparent Optical Module (TOM) 2.0 at Vision Expo East 2024https://modernod.com/news/newsight-reality-unveils-transparent-optical-module-tom-20-at-vision-expo-east-2024/2482167/NewSight Reality (NSR), a provider of Augmented Reality (AR) technologies, announced the next generation of its Transparent Optical Module (TOM) 2.0 at the Vision Expo East meeting. Highlights of the new technology include a patented stray light shielding solution, active micro-len
- Phase 1b/2a Trial of Exonate's Eye Drop Demonstrates Safety and Biological Activity in Treatment of DR and DMEhttps://modernod.com/news/phase-1b2a-trial-of-exonates-eye-drop-demonstrate-safety-and-biological-activity-in-treatment-of-dr-and-dme/2482148/UK-based Exonate announced data from a phase 1b/2a trial for lead candidate EXN407 demonstrating safety and tolerability of the drug candidate, as well as clear indications of biological activity, according to a company news release. The data position the company for further development
- Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual Meetinghttps://modernod.com/news/nicox-announces-presentation-of-data-on-ncx-470-at-the-2024-american-glaucoma-society-annual-meeting/2482143/Nicox SA provided details of poster presentations highlighting data on NCX 470 at the 2024 American Glaucoma Society (AGS) annual meeting, one of the key scientific events in vision research, which was held February 29-March 3, 2024, in Huntington Beach, California. Poster tit
- Optos Celebrates Milestones: 25,000 Devices Installed Globally and Extensive Clinical Publications Achievedhttps://modernod.com/news/optos-celebrates-milestones-25000-devices-installed-globally-and-extensive-clinical-publications-achieved/2482131/Optos announced a dual milestone achievement of over 25,000 devices installed worldwide, and the collection of 2,500 clinical and peer-reviewed studies spanning 235 disease states, acccording to a company news release. "This remarkable double milestone reflects the unwavering
- Alcon to Unveil Updated MARLO App at SECO 2024https://modernod.com/news/alcon-to-unveil-new-marlo-app-at-seco-2024/2482127/Alcon announced it will showcase the new MARLO App at the SECO International meeting in Atlanta. The app includes new features for patients and is now available to download in the Apple App Store. Launched in 2020, MARLO was developed as an online platform to h
- WashU Awarded up to $20M to Create Portable Device to Scan for Eye Diseaseshttps://modernod.com/news/washu-awarded-up-to-20m-to-create-portable-device-to-scan-for-eye-diseases/2482115/Chao Zhou, a professor of biomedical engineering in the McKelvey School of Engineering at Washington University in St. Louis, has been working to improve optical coherence tomography (OCT) systems that can conduct high-resolution imaging of the eyes. Now, with an up to $20 million contract from t
- EyeBio Announces Positive Visual, Anatomic and Safety Data from First-in-Human Ph1b/2a AMARONE Trial of Restorethttps://modernod.com/news/eyebio-announces-positive-visual-anatomic-and-safety-data-from-first-in-human-ph1b2a-amarone-trial-of-restoret/2482112/Eyebiotech announced the presentation of Week 12 data from its first-in-human phase 1b/2a AMARONE trial of Restoret in patients with treatment-naïve diabetic macular edema (DME) and treatment-naïve wet age-related macular degeneration (AMD). The analysis was presented by Charles C.
- Nicox Announces Presentations at the Upcoming ARVO Annual Meeting 2024https://modernod.com/news/nicox-announces-presentations-at-the-upcoming-arvo-annual-meeting-2024/2482100/Nicox SA announced presentations on NCX 470 and NCX 1728 at the upcoming Association for Research in Vision and Ophthalmology (ARVO) annual meeting, May 5-9, 2024 in Seattle. Abstract/Presentation Title: Tolerability and intraocular pressure (IOP)-lowering efficacy
- Lineage's RG6501 (OpRegen) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Meetinghttps://modernod.com/news/lineages-rg6501-opregen-phase-12a-results-will-be-featured-at-2024-angiogenesis-meeting/2482068/Lineage Cell Therapeutics announced that results showing retinal structure improvements with RG6501 (OpRegen) from a phase 1/2a clinical study (ClinicalTrials.gov Identifier: